このエントリーをはてなブックマークに追加
ID 51468
FullText URL
Author
Kurose, Yuko
Kanzaki, Motoko
Inoue, Kentaro
Terami, Takahiro
Katayama, Akihiro
Watanabe, Mayu
Higuchi, Chigusa
Miyatake, Nobuyuki
Abstract
Background: Galectin-9 (Gal-9) induces apoptosis in activated T helper 1 (T(H)1) cells as a ligand for T cell immunoglobulin mucin-3 (Tim-3). Gal-9 also inhibits the G1 phase cell cycle arrest and hypertrophy in db/db mice, the hallmark of early diabetic nephropathy, by reversing the high glucose-induced up-regulation of cyclin dependent kinase inhibitors such as p27(Kip1) and p21(Cip1). Methods: We investigated the serum levels of Gal-9 in the patients with type 2 diabetes and various stages of chronic kidney disease (CKD) (n = 182). Results: Serum Gal-9 levels in the patients with type 2 diabetes were 131.9 +/- 105.4 pg/ml and Log(10)Gal-9 levels significantly and positively correlated with age (r = 0.227, p = 0.002), creatinine (r = 0.175, p = 0.018), urea nitrogen (r = 0.162, p = 0.028) and osmotic pressure (r = 0.187, p = 0.014) and negatively correlated with estimated glomerular filtration rate (eGFR) (r = -0.188, p = 0.011). Log(10)Gal-9 levels increased along with the progression of GFR categories of G1 to G4, and they were statistically significant by Jonckheere-Terpstra test (p = 0.012). Log(10)Gal-9 levels remained similar levels in albuminuria stages of A1 to A3. Conclusion: The elevation of serum Gal-9 in the patients with type 2 diabetes is closely linked to GFR and they may be related to the alteration of the immune response and inflammation of the patients with type 2 diabetes and CKD.
Keywords
Type 2 diabetes
Glomerular filtration
Inflammation
Kidney disease
Nephropathy
Published Date
2013-01-22
Publication Title
BMC Nephrology
Volume
volume14
Publisher
Biomed Central Ltd
ISSN
1471-2369
Content Type
Journal Article
Official Url
http://dx.doi.org/10.1186/1471-2369-14-23
Related Url
http://ousar.lib.okayama-u.ac.jp/metadata/51451
language
英語
File Version
publisher
Refereed
True
DOI
Web of Sience KeyUT